Long-term safety of spironolactone in acne: Results of an 8-year followup study

被引:65
作者
Shaw, JC
White, LE
机构
[1] Univ Toronto, Toronto Western Hosp, Div Dermatol, Toronto, ON M5T 2S8, Canada
[2] Macneal Mem Hosp, Dept Med, Berwyn, IL USA
关键词
D O I
10.1007/s10227-001-0152-4
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Spironolactone has been used for over 20 years as an antiandrogen in the treatment of acne and hirsutism. No long-term studies of the safety of spironolactone used in this manner have been published. We present a study of the long-term safety and tolerance of spironolactone in 91 women with acne who were followed for up to 8 years. Methods. A survey questionnaire was sent to 210 patients, and a comparison chart review of all patients to whom the survey was sent was made. Results. Ninety-one completed surveys were analyzed, comprising 506 person-years of followup and 200 person-years of spironolactone exposure. Mean treatment length was 28.5 months (range = 0.5--122 months). During the 8-year followup period, there were no cases of serious illness attributable to spironolactone use. Side effects were present in 59% and resulted in cessation of the drug in 15%. Diuretic effect and menstrual irregularities were the most common adverse effects. Conclusions: After 200 person-years of exposure to spironolactone and 506 person-years of followup over 8 years, no serious illnesses thought to be attributed to spironolactone were reported. The long-term use of spironolactone in the treatment of acne in women appears to be safe. Side effects, however, are common, although not usually a cause for stopping the drug.
引用
收藏
页码:541 / 545
页数:5
相关论文
共 10 条
  • [1] BARKER DJP, 1987, J DRUG DEV S2, V1, P22
  • [2] NON-ESTROGENIC DRUGS AND BREAST-CANCER
    DANIELSON, DA
    JICK, H
    HUNTER, JR
    STERGACHIS, A
    MADSEN, S
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1982, 116 (02) : 329 - 332
  • [3] INITIAL SCREENING FOR CARCINOGENICITY OF COMMONLY USED DRUGS
    FRIEDMAN, GD
    URY, HK
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1980, 65 (04) : 723 - 733
  • [4] ORAL SPIRONOLACTONE IMPROVES ACNE-VULGARIS AND REDUCES SEBUM EXCRETION
    GOODFELLOW, A
    ALAGHBANDZADEH, J
    CARTER, G
    CREAM, JJ
    HOLLAND, S
    SCULLY, J
    WISE, P
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1984, 111 (02) : 209 - 214
  • [5] TOLERANCE OF SPIRONOLACTONE
    HUGHES, BR
    CUNLIFFE, WJ
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1988, 118 (05) : 687 - 691
  • [6] LEE O, 2000, COCHRANE DB SYST REV, P194
  • [7] BREAST-CANCER ASSOCIATED WITH ADMINISTRATION OF SPIRONOLACTONE
    LOUBE, SD
    QUIRK, RA
    [J]. LANCET, 1975, 1 (7922) : 1428 - 1429
  • [8] Low-dose adjunctive spironolactone in the treatment of acne in women: A retrospective analysis of 85 consecutively treated patients
    Shaw, JC
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (03) : 498 - 502
  • [9] SPIRONOLACTONE IN DERMATOLOGICAL THERAPY
    SHAW, JC
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 24 (02) : 236 - 243
  • [10] The human sebocyte culture model provides new insights into development and management of seborrhoea and acne
    Zouboulis, CC
    Xia, L
    Akamatsu, H
    Seltmann, H
    Fritsch, M
    Hornemann, S
    Rühl, R
    Chen, W
    Nau, H
    Orfanos, CE
    [J]. DERMATOLOGY, 1998, 196 (01) : 21 - 31